To accelerate the formation of new quality productive forces, shape new drivers and advantages for development, and support the high-quality economic and social development of Taizhou, the Taizhou Municipal Science and Technology Bureau recently announced the recognition of JumpCan (Shanghai) Medical Technology Co., Ltd., applied for by JumpCan Pharmaceutical Group, as one of the first batch of enterprise offshore innovation centers in Taizhou, which was officially recognized. JumpCan (Shanghai) Medical will receive government subsidies in areas such as construction and operation, project application, R&D subsidies, and financial support. R&D talents working at the offshore innovation center will be treated as Taizhou local employees and enjoy the same talent policies.
Enterprise offshore innovation centers serve as important bases for technological research and development, aiming to promote the deep integration of local enterprises with scientific and technological resources in advanced regions, accelerate the transformation and application of scientific and technological achievements, and inject new momentum into regional economic and social development. Through offshore innovation centers, enterprises can attract and cultivate high-level innovative talents, providing talent support for long-term development. At the same time, these centers can also leverage external scientific, talent, and market resources.
JumpCan (Shanghai) Medical Technology Co., Ltd., established in 2017 and located in the Shanghai Pudong New Area International Medical Park, is an independent legal entity and an innovative R&D platform under its parent company, JumpCan Pharmaceutical Group. It is recognized as a National High-Tech Enterprise, a Shanghai Specialized, Refined, Unique, and New SME, a Shanghai Innovative SME, and has been certified as an enterprise R&D institution by the Pudong New Area.
The company focuses on pediatrics, respiratory, digestive, neuropsychiatric, and gynecological fields, with a foundation in high-complexity generic drugs and breakthroughs in improved new drugs, small molecule innovative drugs, and innovative TCM drugs. It continues to strengthen its innovation capacity building and enhancement. In recent years, leveraging regional advantages, the company has actively introduced 21 high-level talents, forming an innovative team of 150 people across eight disciplinary areas, led by Shanghai Industrial Elite Young Talents, Shanghai Outstanding Technical Leaders, Eastern Talent Plan Youth Talents, and Pudong New Area Pearl Leading Talents. Doctoral and master's degree holders account for 61% of the team. The company has completed over 140 TCM and chemical drug R&D projects, developed more than 10 new varieties, and has over 20 projects in progress. Several products have broken through industry technical bottlenecks and achieved rapid market entry, such as Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution , the first generic version launched domestically, and Xiao'er Chiqiao Qingre Syrup, the first improved new drug approved under the new TCM registration classification.